CA3019981A1 - Nucleic acid linked to a trivalent glycoconjugate - Google Patents
Nucleic acid linked to a trivalent glycoconjugate Download PDFInfo
- Publication number
- CA3019981A1 CA3019981A1 CA3019981A CA3019981A CA3019981A1 CA 3019981 A1 CA3019981 A1 CA 3019981A1 CA 3019981 A CA3019981 A CA 3019981A CA 3019981 A CA3019981 A CA 3019981A CA 3019981 A1 CA3019981 A1 CA 3019981A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- glycoconjugate
- trivalent
- acid linked
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163939.8 | 2016-04-05 | ||
| EP16163939.8A EP3228326A1 (en) | 2016-04-05 | 2016-04-05 | Nucleic acid linked to a trivalent glycoconjugate |
| PCT/EP2017/058112 WO2017174657A1 (en) | 2016-04-05 | 2017-04-05 | Nucleic acid linked to a trivalent glycoconjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3019981A1 true CA3019981A1 (en) | 2017-10-12 |
Family
ID=55697082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3019981A Pending CA3019981A1 (en) | 2016-04-05 | 2017-04-05 | Nucleic acid linked to a trivalent glycoconjugate |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10913945B2 (https=) |
| EP (3) | EP3228326A1 (https=) |
| JP (1) | JP7120925B2 (https=) |
| CN (2) | CN116036117A (https=) |
| AU (1) | AU2017245687B2 (https=) |
| CA (1) | CA3019981A1 (https=) |
| DK (1) | DK3439703T3 (https=) |
| ES (1) | ES2805026T3 (https=) |
| HU (1) | HUE049931T2 (https=) |
| PL (1) | PL3439703T3 (https=) |
| WO (1) | WO2017174657A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202008301UA (en) * | 2016-04-11 | 2020-10-29 | Arbutus Biopharma Corp | Targeted nucleic acid conjugate compositions |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| WO2019193144A1 (en) | 2018-04-05 | 2019-10-10 | Silence Therapeutics Gmbh | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND |
| EP3550022A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Products and compositions |
| WO2018185252A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Nucleic acid conjugates |
| JP7155239B2 (ja) * | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| WO2018185240A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| EP3385272A1 (en) * | 2017-04-05 | 2018-10-10 | Silence Therapeutics GmbH | Further novel oligonucleotide-ligand conjugates |
| EP4029942A1 (en) | 2017-04-05 | 2022-07-20 | Silence Therapeutics GmbH | Products and compositions |
| EP3483269A1 (en) | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| IL274611B2 (en) * | 2017-11-13 | 2024-10-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| CA3118327A1 (en) | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| EP3483270A1 (en) | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| EP3549610A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Nucleic acid conjugates |
| EP3550021A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Products and compositions for inhibiting expression of a target gene |
| EP3598995A1 (en) | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
| BR112021009213A2 (pt) | 2018-11-13 | 2021-08-10 | Silence Therapeutics Gmbh | ácidos nucleicos para inibição da expressão de lpa em uma célula |
| EP3730617A1 (en) | 2019-04-26 | 2020-10-28 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of c3 in a cell |
| CA3119234A1 (en) | 2018-11-23 | 2020-05-28 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| EP3886851A1 (en) | 2018-11-26 | 2021-10-06 | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE | Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease |
| WO2020225301A1 (en) | 2019-05-07 | 2020-11-12 | Universität Bern | Nucleic acids for inhibiting expression of pros1 in a cell |
| EP4022060A1 (en) | 2019-08-27 | 2022-07-06 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of c3 in a cell |
| EP4025252A4 (en) | 2019-09-03 | 2023-10-18 | Arcturus Therapeutics, Inc. | ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ADMINISTRATION OF THERAPEUTICALLY ACTIVE CONJUGATES |
| EP4048801A4 (en) * | 2019-10-24 | 2023-11-22 | Genevant Sciences Gmbh | Conjugates and methods for treating acromegaly |
| US20240229041A2 (en) | 2020-05-27 | 2024-07-11 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Nucleic acids for inhibiting expression of cnnm4 in a cell |
| WO2022096424A1 (en) | 2020-11-04 | 2022-05-12 | Universität Bern | Nucleic acids for inhibiting expression of pros1 in a cell |
| AU2021373262A1 (en) | 2020-11-04 | 2023-06-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of pros1 in a cell |
| WO2022184852A1 (en) | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| WO2022223557A1 (en) | 2021-04-20 | 2022-10-27 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of xdh in a cell |
| US20240240187A1 (en) | 2021-04-27 | 2024-07-18 | Silence Therapeutics Gmbh | Sirna targeting tmprss6 for the treatment of myeloproliferative disorders |
| KR20240051221A (ko) | 2021-09-02 | 2024-04-19 | 사일런스 테라퓨틱스 게엠베하 | 세포에서 보체 인자 b (cfb)의 발현을 억제하기 위한 핵산 |
| JP2024541559A (ja) * | 2021-11-29 | 2024-11-08 | シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド | Ｂ型肝炎ウイルス（ｈｂｖ）タンパク質の発現を阻害するための組成物および方法 |
| WO2023208106A1 (zh) * | 2022-04-29 | 2023-11-02 | 石药集团中奇制药技术（石家庄）有限公司 | 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| WO2024126687A1 (en) | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| EP4687983A1 (en) | 2023-03-27 | 2026-02-11 | Silence Therapeutics GmbH | Compounds and compositions for use in stem cell transplantation |
| CN116444589B (zh) * | 2023-06-15 | 2023-09-19 | 北京悦康科创医药科技股份有限公司 | 新型GalNAc化合物及其硫代寡核苷酸缀合物和偶联方法 |
| US20250051771A1 (en) | 2023-07-24 | 2025-02-13 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311334D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311324D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025132845A1 (en) | 2023-12-21 | 2025-06-26 | Silence Therapeutics Gmbh | Galnac phosphoramidites and their uses |
| WO2025162939A1 (en) | 2024-01-29 | 2025-08-07 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of gpr146 in a cell |
| WO2025163186A1 (en) | 2024-02-01 | 2025-08-07 | Silence Therapeutics Gmbh | Conjugated nucleic acids and nucleic acids comprising locked nucleosides and inverted nucleotides for inhibiting gene expression in a cell |
| WO2025169133A1 (en) | 2024-02-09 | 2025-08-14 | Astrazeneca Ab | Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof |
| US20260015617A1 (en) | 2024-07-12 | 2026-01-15 | Novartis Ag | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE |
| US12454693B1 (en) * | 2024-09-27 | 2025-10-28 | Dexcel Pharma Technologies Ltd. | Nucleic acids for inhibiting expression of transferrin receptor 2 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| AU3751299A (en) | 1998-04-20 | 1999-11-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US10077443B2 (en) * | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| DK2991656T3 (da) * | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| PT3137605T (pt) * | 2014-05-01 | 2020-12-18 | Ionis Pharmaceuticals Inc | Composições e métodos para modulação da expressão de angiopoietina de tipo 3 |
| WO2016055601A1 (en) * | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
-
2016
- 2016-04-05 EP EP16163939.8A patent/EP3228326A1/en not_active Ceased
-
2017
- 2017-04-05 JP JP2018552707A patent/JP7120925B2/ja active Active
- 2017-04-05 US US16/091,503 patent/US10913945B2/en active Active
- 2017-04-05 DK DK17715730.2T patent/DK3439703T3/da active
- 2017-04-05 EP EP17715730.2A patent/EP3439703B1/en active Active
- 2017-04-05 CN CN202211456959.7A patent/CN116036117A/zh active Pending
- 2017-04-05 ES ES17715730T patent/ES2805026T3/es active Active
- 2017-04-05 HU HUE17715730A patent/HUE049931T2/hu unknown
- 2017-04-05 EP EP20171464.9A patent/EP3744350A1/en active Pending
- 2017-04-05 CA CA3019981A patent/CA3019981A1/en active Pending
- 2017-04-05 PL PL17715730T patent/PL3439703T3/pl unknown
- 2017-04-05 WO PCT/EP2017/058112 patent/WO2017174657A1/en not_active Ceased
- 2017-04-05 CN CN201780035060.9A patent/CN109562188B/zh active Active
- 2017-04-05 AU AU2017245687A patent/AU2017245687B2/en active Active
-
2020
- 2020-11-25 US US17/104,502 patent/US11912993B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3439703T3 (da) | 2020-06-29 |
| CN116036117A (zh) | 2023-05-02 |
| US20210079397A1 (en) | 2021-03-18 |
| JP7120925B2 (ja) | 2022-08-17 |
| EP3744350A1 (en) | 2020-12-02 |
| US10913945B2 (en) | 2021-02-09 |
| ES2805026T3 (es) | 2021-02-10 |
| EP3439703A1 (en) | 2019-02-13 |
| WO2017174657A1 (en) | 2017-10-12 |
| AU2017245687B2 (en) | 2023-03-09 |
| CN109562188A (zh) | 2019-04-02 |
| JP2019510793A (ja) | 2019-04-18 |
| AU2017245687A1 (en) | 2018-10-25 |
| EP3439703B1 (en) | 2020-04-29 |
| EP3228326A1 (en) | 2017-10-11 |
| CN109562188B (zh) | 2022-12-06 |
| PL3439703T3 (pl) | 2020-10-19 |
| US11912993B2 (en) | 2024-02-27 |
| US20190119676A1 (en) | 2019-04-25 |
| HUE049931T2 (hu) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3019981A1 (en) | Nucleic acid linked to a trivalent glycoconjugate | |
| WO2016061286A3 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| WO2018064165A3 (en) | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | |
| EP4339288A3 (en) | Oligonucleotide probes and uses thereof | |
| HK1205453A1 (en) | Methods of diagnosing and treating motor neuron diseases | |
| SG11201806372UA (en) | Nucleic acid conjugate | |
| WO2018091740A3 (en) | Novel anti_cd137 antibodies and uses thereof | |
| HK1252759A1 (zh) | 肽寡核苷酸缀合物 | |
| WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| WO2010141511A3 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
| WO2018094190A3 (en) | Gut microbiota and treatment of cancer | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| EP4559902A3 (en) | Kdm1a inhibitors for the treatment of disease | |
| WO2016100261A3 (en) | Method of treating cancer with cgamp or cgasmp | |
| WO2009062195A3 (en) | Fusion proteins of mannose binding lectins for treatment of disease | |
| BR112015004501A2 (pt) | derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo | |
| WO2011020783A3 (en) | Targeted immunoconjugates | |
| WO2004065423A3 (de) | Erkennungsmoleküle zur behandlung und detektion von tumoren | |
| WO2007089945A3 (en) | Treating diseases by targeting silt3 | |
| WO2012158780A3 (en) | Lung cancer signature | |
| WO2015191934A8 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| WO2015066053A3 (en) | Targeted therapeutics | |
| WO2015168521A8 (en) | P97-polynucleotide conjugates | |
| WO2014057436A3 (en) | Anticancer conjugate | |
| WO2008108830A3 (en) | Immunogenic and therapeutic compositions for streptococcus pyogenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241112 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250828 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20250828 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250828 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250828 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250828 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260316 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260408 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260408 |